Results 221 to 230 of about 4,347,639 (355)
Nonclinical pharmacology and toxicology studies of LY01620, a therapeutic mRNA vaccine against human papillomavirus 16-related cancers [PDF]
Guangying Du +4 more
openalex +1 more source
ABSTRACT Modified Vaccinia virus Ankara (MVA) is a potent vector for the development of vaccines and novel cancer treatment strategies. Since it is a non‐replicating virus in human recipients, high infective titers are required for therapeutic efficacy.
Linus G. Weber +5 more
wiley +1 more source
From stimulator of interferon genes (STING) agonism to STING programming: Opportunities for mRNA cancer vaccines. [PDF]
Zhou Z, Qin Q, Han C.
europepmc +1 more source
Programmable three‐state nanoreactor for spatiotemporally controlled tumor therapy
The OMVs are shielded with a biocompatible Da–Ca shell, which prolongs its circulation period and promotes intratumoral accumulation. Importantly, the biocompatible Da–Ca shell can be controllably disintegrated in tumor microenvironment by using laser irradiation, generating in situ hyperthermia and releasing Ca2+.
Guihong Lu +12 more
wiley +1 more source
mRNA cancer vaccines: delivery strategies, immune modulation, and clinical translation. [PDF]
Tian D +10 more
europepmc +1 more source
Tackling cancer stemness with nanotechnology in the era of precision medicine
Precise customization of nanoparticles (NPs) enables active targeting of cancer stem cells (CSCs), thereby improving drug delivery and therapeutic efficacy. NP‐based probing enhances CSC detection through imaging and liquid biopsy, whereas diverse therapeutic payloads improve therapeutic outcomes.
Shaolei Guo +9 more
wiley +1 more source
Cancer Vaccines in Genitourinary Malignancies: Current Advances and Future Directions. [PDF]
Altay H +4 more
europepmc +1 more source

